NeoGenomics (NASDAQ:NEO) Releases Earnings Results, Beats Expectations By $0.02 EPS

NeoGenomics (NASDAQ:NEO) posted its quarterly earnings data on Tuesday. The medical research company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.02, FiscalAI reports. NeoGenomics had a negative return on equity of 2.80% and a negative net margin of 13.30%.The firm had revenue of $201.66 million for the quarter, compared to the consensus estimate of $196.93 million. During the same quarter in the previous year, the business earned $0.03 EPS. The company’s quarterly revenue was up 11.2% compared to the same quarter last year.

Here are the key takeaways from NeoGenomics’ conference call:

• Second-quarter revenue rose 11% to $201.7 million, exceeding guidance, while clinical revenue increased 14% on 2% volume growth and a 12% increase in average revenue per test.
• NGS revenue grew 26% year over year, driven by 14% volume growth and continued migration toward larger, higher-value panels. Management raised its full-year NGS growth outlook to the mid-20% range.
• Adjusted gross margin expanded 260 basis points to 48.1%, and adjusted EBITDA increased 36% to $14.4 million, supported by favorable test mix, pricing initiatives, operating discipline, and the Lab of the Future program.
• Management raised 2026 revenue guidance to $802 million-$806 million and adjusted EBITDA guidance to $56 million-$58 million, citing strong clinical momentum and expected continued margin improvement.
• Non-clinical revenue declined 15%, including a 26% drop in pharma revenue, leading the company to lower its 2026 non-clinical outlook to a high-single-digit decline. Management expects pharma to return to growth in 2027, but this depends on converting bookings into revenue and securing additional projects.

NeoGenomics Stock Up 2.0%

NEO stock opened at $13.40 on Wednesday. The stock has a market cap of $1.74 billion, a P/E ratio of -17.40 and a beta of 1.74. The company has a current ratio of 4.42, a quick ratio of 4.06 and a debt-to-equity ratio of 0.41. NeoGenomics has a twelve month low of $4.72 and a twelve month high of $15.57. The company’s 50 day moving average is $12.39 and its two-hundred day moving average is $10.65.

Insider Activity

In related news, Director Lynn A. Tetrault sold 5,307 shares of the stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $11.29, for a total value of $59,916.03. Following the transaction, the director directly owned 91,422 shares of the company’s stock, valued at $1,032,154.38. This trade represents a 5.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.10% of the company’s stock.

Hedge Funds Weigh In On NeoGenomics

Several large investors have recently bought and sold shares of the stock. CIBC Bancorp USA Inc. purchased a new position in shares of NeoGenomics during the third quarter worth about $106,000. Moors & Cabot Inc. lifted its holdings in shares of NeoGenomics by 14.6% in the 3rd quarter. Moors & Cabot Inc. now owns 13,750 shares of the medical research company’s stock valued at $106,000 after purchasing an additional 1,750 shares during the last quarter. State of Wyoming boosted its position in shares of NeoGenomics by 243.1% in the 2nd quarter. State of Wyoming now owns 13,899 shares of the medical research company’s stock valued at $102,000 after purchasing an additional 9,848 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of NeoGenomics by 604.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 13,878 shares of the medical research company’s stock valued at $101,000 after purchasing an additional 11,908 shares during the period. Finally, Cresset Asset Management LLC purchased a new position in NeoGenomics during the 3rd quarter worth approximately $85,000. Institutional investors and hedge funds own 98.50% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Leerink Partners raised NeoGenomics from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $12.00 to $25.00 in a research report on Wednesday, April 29th. Weiss Ratings raised shares of NeoGenomics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 14th. Wall Street Zen upgraded shares of NeoGenomics from a “hold” rating to a “buy” rating in a report on Saturday, June 27th. Benchmark upped their target price on shares of NeoGenomics from $11.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, July 24th. Finally, TD Cowen reiterated a “buy” rating on shares of NeoGenomics in a report on Wednesday, July 15th. Six investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $15.14.

NeoGenomics News Summary

Here are the key news stories impacting NeoGenomics this week:

• Positive Sentiment: Q2 earnings beat expectations: NeoGenomics reported adjusted earnings of $0.05 per share, compared with the $0.03 FactSet consensus estimate. Revenue reached $201.66 million, exceeding expectations of $196.93 million and increasing 11.2% year over year. NeoGenomics Q2 Earnings Snapshot
• Positive Sentiment: Full-year revenue outlook raised: Management forecast 2026 revenue of $802 million to $806 million, above the analyst consensus of approximately $800.3 million. The increased outlook reinforces the positive reaction to the quarterly results. NeoGenomics Reports Second Quarter 2026 Results
• Positive Sentiment: Results presentation highlighted operating momentum: The earnings materials and conference coverage focused on stronger profit and sales performance, with the company exceeding second-quarter expectations and improving its annual outlook. NeoGenomics 2026 Q2 Results Earnings Call Presentation
• Neutral Sentiment: Analyst consensus remains Hold: Despite the earnings beat and guidance increase, NeoGenomics continues to carry a consensus “Hold” rating, indicating that investors may want additional evidence of sustained profitability. NeoGenomics Receives Consensus Hold Rating
• Negative Sentiment: Profitability remains a concern: The company continues to report a negative net margin and negative return on equity, while analysts still expect a full-year loss, which could limit further upside if operating improvements do not continue.

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.